Procter & Gamble (NYSE:PG | PG Price Prediction) sits at a crossroads familiar to every Dividend King: prove the model still has legs, or watch capital rotate to faster growers. After a foundation-building fiscal 2026 that delivered five straight EPS beats but only flat organic sales in Q4, the setup into fiscal 2027 looks better than the headlines suggest.
P&G trades at $146.10 as of July 29, 2026. Our 24/7 Wall St. price target is $164.75, implying 12.77% upside over the next 12 months. That earns a buy rating with a 90% confidence score, our highest tier.
| Metric | Value |
|---|---|
| Current Price | $146.10 |
| 24/7 Wall St. Price Target | $164.75 |
| Upside | 12.77% |
| Recommendation | BUY |
| Confidence Level | 90% |
A Year of Foundation Building
The stock is down 4% over the last year and off 1.31% this past week, but up 4.18% year to date. Q4 FY2026 delivered core EPS of $1.43 against a $1.407 estimate, with full-year revenue of $87.03 billion and full-year core EPS of $6.89.
Free cash flow expanded 12.74% to $15.84 billion, which matters because CEO Shailesh Jejurikar committed to $10 billion in dividends and $5 billion in buybacks in FY27, funded by operating cash flow.
Why Bulls See a Breakout Ahead
The bull case rests on Beauty, which grew 6% organically in Q4 and posted 11% growth in Q3, driven by SK-II premium mix and Hair Care innovation. Jejurikar told investors P&G is “inventing the CPG company of the future” through Supply Chain 3.0 and AI-enabled molecular discovery.
The bull scenario points to $173.99 (a 19.09% return) if user-growth initiatives reaccelerate volume and productivity savings (Q4 hit 460 bps) fully offset tariff drag.
The Risks Worth Watching
FY27 carries a $1 billion after-tax commodity, energy and transport headwind plus $0.56 per share drag from tariffs, interest and FX. Baby, Feminine & Family Care declined 1% in Q4 and Greater China volumes remain soft in Skin Care and Oral Care.
A recently resolved Polymarket contract showed the crowd underestimated Q4 weakness. Bulls counter that the SG&A surge of 160 bps reflects marketing reinvestment aimed at funding user growth. The bear scenario floors at $151.67, still a 3.81% gain with dividends.
How P&G Compares to Colgate and Kimberly-Clark
Colgate-Palmolive (NYSE:CL) is the cleanest direct comp on oral and personal care. Colgate trades at a forward P/E of 24 with a 2.26% dividend yield, but its most recent quarterly earnings growth was negative 5.9%. P&G’s 21 forward P/E and superior 5.8% earnings growth make our target reasonable rather than aggressive.
Kimberly-Clark (NASDAQ:KMB) offers the valuation contrast. Kimberly-Clark trades at a forward P/E of just 15 with a 4.47% yield, reflecting slower growth in paper-based staples. That gap explains why P&G commands a premium and why our Price Target implies multiple stability rather than expansion.
| Company | Forward P/E | Div Yield |
|---|---|---|
| P&G | 21 | 2.84% |
| Colgate-Palmolive | 24 | 2.26% |
| Kimberly-Clark | 15 | 4.47% |
P&G Price Prediction 2026 to 2030
The 24/7 Wall St. price target of $164.75 and buy rating rest on a durable dividend, expanding free cash flow, and a Beauty segment that compounds.
The setup favors investors who value a 0.38-beta compounder with 70 years of raises and can wait for FY27 tariff headwinds to lap. Investors who need volume-led growth today may find the setup less compelling, since organic sales were flat in two of four quarters this year.
Here is where our model projects P&G could trade, assuming current growth trajectories and capital return policies hold.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $155 |
| 2027 | $164.75 |
| 2028 | $180 |
| 2029 | $199 |
| 2030 | $220 |
These projections assume P&G continues executing the productivity and premiumization playbook. Significant upside or downside could result from sharper reacceleration in user growth or a prolonged tariff and commodity cycle outlasting the FY27 reinvestment plan.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks